Agenus announces new data from expanded mss metastatic colorectal cancer cohort to be presented at esmo gi 2025

Lexington, mass.--(business wire)--agenus inc. (“agenus” or the company”) (nasdaq: agen), a leader in immuno-oncology, today announced new data from its ongoing phase 1 trial evaluating botensilimab and balstilimab (bot/bal) in patients with microsatellite stable (mss) metastatic colorectal cancer (mcrc) at the 2025 european society for medical oncology (esmo) gastrointestinal cancers congress in barcelona, spain. a poster presentation will feature updated findings from an expanded cohort of 12.
AGEN Ratings Summary
AGEN Quant Ranking